During the 2nd National Cancer Research Institute (NCRI) AML Academy meeting, which took place on October 8–9, 2020, we spoke to Executive Steering Committee Member Charles Craddock, Queen Elizabeth Hospital, Birmingham, UK, about the NCRI AML20 trial.
The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
An update on the NCRI AML20 trial
An update on the NCRI AML20 trial
In this video, Charles Craddock describes the three main questions the trial aims to address, including whether the addition of venetoclax can improve the activity of CPX-351 in adults with AML. He also discusses the challenges of opening the trial due to COVID-19.
More about...
Your opinion matters
Which talk topic are you most looking forward to at ASH?
1 vote - 2 days left ...
Related articles
Newsletter
Subscribe to get the best content related to AML delivered to your inbox